Navigation Links
Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C

TITUSVILLE, N.J., Nov. 1, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV). The regimen will include Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue HCV polymerase inhibitor VX-135. As a first step, Janssen will conduct a drug-drug interaction (DDI) study with simeprevir and VX-135. The DDI study will support the initiation of the Phase 2 study in early 2013 pending discussions with regulatory authorities.

The goal of the Phase 2 study will be to evaluate the safety, tolerability and viral cure rates of a 12-week regimen of simeprevir and VX-135, administered with and without ribavirin, in treatment-naive patients who have chronic non-cirrhotic genotype 1 HCV. The companies will jointly fund development costs associated with the collaboration. There are no up-front or milestone payments associated with the agreement.

Simeprevir is an investigational NS3/4A protease inhibitor currently in Phase 3 trials, developed in collaboration with and licensed from Medivir AB. VX-135 is an investigational uridine nucleotide analogue pro-drug designed to inhibit the replication of HCV by acting on the NS5B polymerase. 

"There is a significant unmet need for all-oral treatment regimens for people living with hepatitis C," said Wim Parys, Global Head of Infectious Diseases at Janssen. "Janssen's collaboration with Vertex underscores our commitment to better understand the potential utility of simeprevir in a number of different interferon-free treatment combinations and HCV patient populations."

About Simeprevir
Simeprevir (TMC435) is an NS3/4A protease inhibitor jointly developed by Janssen and Medivir AB to treat chronic HCV infection. Simeprevir is being studied in combination with pegylated interferon and ribavirin, and in combination with direct-acting antiviral (DAA) agents in all-oral interferon-free regimens, with and without ribavirin.

Global Phase 3 studies of simeprevir include QUEST-1 and QUEST-2 in treatment-naive patients, PROMISE in patients who have relapsed after prior interferon-based treatment and ATTAIN in treatment-experienced patients. In parallel to these trials, Phase 3 studies for simeprevir are ongoing in both treatment-naive and treatment-experienced HIV-HCV co-infected patients, HCV genotype 4 patients and in Japanese HCV genotype 1 patients.

Simeprevir is also being studied in other Phase 2 interferon-free trials, with and without ribavirin, in combination with:

  • Janssen's TMC647055 and ritonavir in treatment-naive, relapser or null-responder HCV genotype 1 patients;
  • Gilead Sciences, Inc.'s sofosbuvir (GS-7977) in null-responder HCV genotype 1 patients; and
  • Bristol-Myers Squibb's daclatasvir (BMS-790052) in treatment-naive or previous null-responder HCV genotype 1 patients.

For additional information about simeprevir, please visit

About Hepatitis C
Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease and liver transplants, is a rapidly evolving treatment area with a clear need for innovative treatments. Approximately 170 to 210 million people are infected with hepatitis C worldwide, with three to four million people newly infected each year.

About Janssen
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Pharmaceuticals, Inc. and Janssen Research & Development are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit for more information.

About Vertex and VX-135
To find out more about Vertex and VX-135 please visit

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents or other intellectual property rights; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at, or on request from Johnson & Johnson. Neither Janssen Pharmaceuticals, Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)


SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
2. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
5. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
6. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
7. Watson Announces Global Generics Management Team
8. Watson Announces New Name -- Actavis -- for Global Operations
9. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
10. Abaxis Announces Exclusive Distribution Agreement with Abbott
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
(Date:11/24/2015)... , Nov. 25, 2015 WuXi PharmaTech (Cayman) ... a leading open-access R&D capability and technology platform company ... operations in China and ... at an extraordinary general meeting of shareholders held today, ... to authorize and approve the previously announced agreement and ...
(Date:11/24/2015)... , Nov. 24, 2015  Natera, ... in non-invasive genetic testing and the analysis ... it will present at the 27 th ... December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., ... financial results, business activities and financial outlook. ...
(Date:11/24/2015)... 24, 2015  In the pharmaceutical industry, companies want ... to quickly uncover new insights, tactics and strategies that ... --> However, organizations often find it ... and ensure that all rules and regulations are met ... major barrier to efficiently launching market research projects is ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... their knowledge and experiences at a live taping of the next CURE ... the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University Hotel & Conference ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... With Thanksgiving ... Insurance is sharing safety tips to help protect your family and vehicle. , According ... around the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety tips from ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester ... University President Carl S. Cleveland III on October 16. , “Katie is very ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Bibliomotion ... and Detroit Taught Me about Reinvention and Diversity by Nancy M. Schlichting, ... suffer, with hospitals failing to adequately address the needs of patients and their families, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... All her life, Don Peck’s mother wondered if ... obituary said she might have been. After a 25-year search for information, Don and ... whom she shared a last name. Turns out, it was Don’s father who was ...
Breaking Medicine News(10 mins):